FERROUS GLYCINE SULFATE

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	2C2H5NO2.Fe.O4S
Molecular Weight	302.041
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Fe++].NCC(O)=O.NCC(O)=O.[O-]S([O-])(=O)=O

InChI

InChIKey=YJYOLOWXCPIBSY-UHFFFAOYSA-L

InChI=1S/2C2H5NO2.Fe.H2O4S/c2*3-1-2(4)5;;1-5(2,3)4/h2*1,3H2,(H,4,5);;(H2,1,2,3,4)/q;;+2;/p-2

HIDE SMILES / InChI

Description
Sources: http://www.drugfuture.com/chemdata/ferroglycine-sulfate.htmlhttp://nj.gov/health/eoh/rtkweb/documents/fs/0928.pdfhttps://www.drugs.com/inactive/ferrous-oxide-389.htmlhttp://www.druglead.com/cds/ferrous-iodide.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/16694502http://www.foodchemadditives.com/products/Ferrous-Lactatehttps://www.ncbi.nlm.nih.gov/pubmed/14116934DOI: 10.1021/ja00949a016 Retrived from http://pubs.acs.org/doi/abs/10.1021/ja00949a016
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/3541174 | https://books.google.ru/books?id=7mxyBgAAQBAJ&pg=PA13&lpg=PA13&dq=%22ferrous+iodide%22+anemia&source=bl&ots=ZGyFhUiJZ4&sig=IZOhRVaGmlwX7GcqgoE6rnCsCa4&hl=ru&sa=X&ved=0ahUKEwjYu7PCyYHUAhWiQpoKHR6cCfcQ6AEIUjAJ#v=onepage&q=%22ferrous%20iodide%22&f=false

There is no information about biological and pharmacological application of Iron(II) fluoride (also known as ferrous fluoride). It is known, that this substance is used to catalyze some organic reactions.

Originator

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2596
Anemia 70 Sources: http://www.medicatione.com/?c=ing&s=ferrous%20aspartate	Palliative	Not Provided 511	Unknown Approved Use Unknown
Unknown 2596
Hypochromic anemia 37 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16694502	Palliative	Not Provided 511	Unknown Approved Use Unknown
Unknown 2596
Unknown 2596
Unknown 2596
Iron deficiency 41 Sources: http://www.minapharm.com/Public/ProductDetails.aspx?ProductCode=FERRO_SANO&langParam=en	Primary	Approved 8583	Ferro Sanol Duodenal Approved Use Ferro Sanol is an iron substitute in case of latent or manifest iron deficiency with and without development of anaemia.
Radioactive cesium and/or radioactive or non-radioactive thallium internal contamination 37 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021626lbl.pdf	Curative	Approved 8583	RADIOGARDASE Approved Use Insoluble Prussian blue is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination. Launch Date 2003
Unknown 2596

PubMed

Title	Date	PubMed
Reactivity enhancement of iron sulfide nanoparticles stabilized by sodium alginate: Taking Cr (VI) removal as an example.	2017-07-05	28371713
Continuous sulfidogenic wastewater treatment with iron sulfide sludge oxidation and recycle.	2017-05-01	28249212
Atomic Layer Deposition of Iron Sulfide and Its Application as a Catalyst in the Hydrogenation of Azobenzenes.	2017-03-13	28170144
Synthesis of phosphabenzenes by an iron-catalyzed [2+2+2] cycloaddition reaction of diynes with phosphaalkynes.	2015-06-22	25981197
A practical and successful desensitization protocol for immediate hypersensitivity reactions to iron salts.	2014	25402762
Effect of abomasal ferrous lactate infusion on phosphorus absorption in lactating dairy cows.	2013-07	23660146
Tolerability of different oral iron supplements: a systematic review.	2013-04	23252877
Endothelial dysfunction and inflammation induced by iron oxide nanoparticle exposure: Risk factors for early atherosclerosis.	2011-06-10	21439359
The effect of iron treatment on adhesion molecules in patients with iron deficiency anemia.	2010-12	20039148
Bioleaching of heavy metals from sewage sludge by indigenous iron-oxidizing microorganisms using ammonium ferrous sulfate and ferrous sulfate as energy sources: a comparative study.	2009-11-15	19586718
Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-mice.	2009	19421372
Decreased treatment failure rates following duodenal release ferrous glycine sulfate in iron deficiency anemia associated with autoimmune gastritis and Helicobacter pylori gastritis.	2007	17426393
Determination of water in ferrous lactate by near infrared reflectance spectroscopy with a fibre-optic probe.	1997-10	9408841
[Historical notes on the therapy of depression].	1986-11-22	3541174
[FERROUS ASPARTATE IN THERAPY].	1964-01-01	14116934
Clinical appraisal of drugs with special reference to a new chelate hematinic.	1957-07-11	13452048
[Ferrous lactate as an oral iron preparation for therapeutic use].	1954-11-27	14348915
THE USE OF FERROUS GLUCONATE IN THE TREATMENT OF HYPOCHROMIC ANEMIA.	1937-07	16694502
FERROUS IODIDE AND LINOLEIC ACID IN VITAMIN A DEFICIENCY. A REPLY TO CERTAIN CRITICISMS.	1932-11-11	17744342
THE ADMINISTRATION OF FERROUS IODIDE AND LINOLEIC ACID TO RATS DEPRIVED OF VITAMIN A.	1932-09-30	17754111
FERROUS IODIDE AS A SUBSTITUTE FOR VITAMIN A IN RATS.	1932-07-01	17815234

Patents

Sample Use Guides

In Vivo Use Guide

Adults should usually take one capsule a day. In cases of pronounced iron deficiency, adults can be given a dosage 2 to 3 times higher at the beginning of therapy. A daily dose of more than 5 mg Fe2+/kg body weight should in-well founded exceptional cases not be exceeded.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

FERROUS GLYCINE SULFATE

Common Name

English

FERROUS GLYCINE SULPHATE

Preferred Name

English

GLYCINE, COMPD. WITH IRON SULFATE (FESO4) (2:1)

Common Name

English

Ferrous glycine sulfate [WHO-DD]

Common Name

English

IRON, BIS(GLYCINATO)-, SULFATE (1:1)

Common Name

English

IRON(II) GLYCINE SULFATE

Common Name

English

Classification Tree Code System Code

WHO-ATC

B03AA01